Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study.

Dear Editor, Despite recent advances, the effects of immune-modulating biologic therapies on the clinical course of COVID-19 remains unclear ([1]). Our findings also corroborate similar studies on SARS-CoV-2 infections in patients with atopic diseases undergoing dupilumab treatment. From the Italian-based DA-COVID-19 registry, Chiricozzi et al. noted that 15 of 1576 patients (0.9%) with AD on dupilumab, either monotherapy or combined therapy, had SARS-CoV-2 infection. [Extracted from the article]